<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555304</url>
  </required_header>
  <id_info>
    <org_study_id>KH903-40101-CRP</org_study_id>
    <nct_id>NCT04555304</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of Weekly Paclitaxel With or Without KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Kanghong Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu Kanghong Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of the study drug known as&#xD;
      KH903 in participants with gastric and gastroesophageal cance&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival（PFS）</measure>
    <time_frame>Time from date of randomization until the date of first documented Progression or date of death from any cause， whichever came frist，assessed up to18 months</time_frame>
    <description>Date of randomization until the date of first documented Progression or date of death from any cause， whichever came first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Time from date of randomization until the date of first documented CR or PR，assessed up to18 months</time_frame>
    <description>Percentage of Participants with a Best Overall Response (BOR) of Partial Response (PR) or Complete Response (CR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time from first documented evidence of CR or PR until the date of first documented progression ，assessed up to18 months</time_frame>
    <description>is defined as the time from first documented evidence of CR or PR until the date of first documented progression as assessed by RECIST 1.1 or death; assessed up to18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Time from date of randomization until the date of first documented Progression，assessed up to18 months</time_frame>
    <description>Percentage of Participants who have achieved CR, PR and SD to study treatment;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>AEs（NCI CTCAE 5.0） collected at each cycle，Assessed up to18 months</time_frame>
    <description>Number of Subjects with treatment-related adverse events (AEs)Defined by all</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>KH903 + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV KH903 4 mg/kg IV paclitaxel 80 mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Placebo IV paclitaxel 80 mg/m²</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KH903 + Paclitaxel</intervention_name>
    <description>KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle</description>
    <arm_group_label>KH903 + Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Paclitaxel</intervention_name>
    <description>Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle</description>
    <arm_group_label>Placebo + Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Prior to any detailed procedures of this study, subjects are able to understand,&#xD;
             voluntarily participate in and sign the informed consent approved by the ethics&#xD;
             committee.&#xD;
&#xD;
          -  2.Age ≥ 18 years.&#xD;
&#xD;
          -  3.Histologically confirmed, unresectable, locally advanced or metastatic gastric or&#xD;
             gastroesophageal junction (GEJ) adenocarcinoma .&#xD;
&#xD;
          -  4.Have at least 1 measurable lesion based on Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST), Version 1.1.&#xD;
&#xD;
          -  5.Have experienced documented objective radiographic or symptomatic disease&#xD;
             progression during first-line therapy, or within 4 months after the last dose of&#xD;
             first-line therapy with any platinum or/and fluoropyrimidine doublet for unresectable&#xD;
             or metastatic disease.Second line chemotherapy is suitable for paclitaxel.&#xD;
&#xD;
          -  6.Laboratory test values must meet the following criteria. ANC ≥1.5×109/L, platelets ≥&#xD;
             100×109/L, hemoglobin≥9g/dL. Blood creatinine ≤ 1.5 ×ULN or creatinine clearance ≥ 50&#xD;
             mL/min/m2. Total bilirubin ≤ 1.5× ULN(≤ 3 x ULN if Gilbert disease), AST and ALT ≤&#xD;
             2.5× ULN (≤ 5×ULN if hepatic metastasis).&#xD;
&#xD;
        INR ≤ 1.5× ULN, APTT ≤ 1.5× ULN. Dipstick proteinuria &lt;2+ or 24 hour proteinuria &lt;1g .&#xD;
&#xD;
          -  7.Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status&#xD;
             (PS) 0 to 1.&#xD;
&#xD;
          -  8.Life expectancy of ≥ 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Histologically confirmed squamous cell carcinoma or undifferentiated gastric cancer.&#xD;
&#xD;
          -  2.Patients with disease progression within 6 months after previous adjuvant or&#xD;
             neoadjuvant chemotherapy with paclitaxel, or patients with recurrent or metastatic&#xD;
             gastric adenocarcinoma or GEJ adenocarcinoma treated with paclitaxel.&#xD;
&#xD;
          -  3. GI perforation and/or fistulae in the 6 months preceding randomization.&#xD;
&#xD;
          -  4.Deep-vein thrombosis, pulmonary embolism (PE), or any other episode of Uncontrolled&#xD;
             thromboembolism in the 6 months preceding randomization.&#xD;
&#xD;
          -  5.Any arterial thromboembolic event (such as myocardial infarction, unstable angina,&#xD;
             cerebrovascular accident or transient ischemic attack)&#xD;
&#xD;
          -  6.Uncontrolled hypertension (≥150/100 mm Hg ) despite properly observed&#xD;
             antihypertensive therapy.&#xD;
&#xD;
          -  7.Known brain metastasis.&#xD;
&#xD;
          -  8.Known allergy to paclitaxel or KH903.&#xD;
&#xD;
          -  9.Serious concurrent infection or medical illness.&#xD;
&#xD;
          -  10.Active hepatitis B virus or Active hepatitis C virus (HCV) infection at screening.&#xD;
&#xD;
          -  11.Any condition which results in an undue risk for the patient during the trial&#xD;
             participation according to the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yi ba, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yi ba, PhD</last_name>
    <phone>13752157916</phone>
    <email>bayi@timuch.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

